Truist Financial Forecasts Strong Price Appreciation for Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics (NASDAQ:BBNX) had its price target hoisted by equities research analysts at Truist Financial from $23.00 to $28.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective points to a potential upside of 28.85% from the stock’s current price.

BBNX has been the topic of a number of other research reports. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Wells Fargo & Company began coverage on shares of Beta Bionics in a research report on Wednesday. They set an “overweight” rating and a $28.00 price objective on the stock. Bank of America increased their price objective on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, September 15th. Leerink Partners boosted their price objective on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, September 14th. Finally, UBS Group reissued a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.91.

Beta Bionics Price Performance

NASDAQ:BBNX traded down $0.46 on Thursday, reaching $21.73. 243,052 shares of the company’s stock were exchanged, compared to its average volume of 1,187,138. The stock has a fifty day simple moving average of $17.98 and a 200-day simple moving average of $14.29. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71. The firm has a market cap of $977.63 million, a price-to-earnings ratio of -13.23 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. As a group, sell-side analysts predict that Beta Bionics will post -2.06 EPS for the current year.

Insider Activity at Beta Bionics

In other news, Director Christy Jones sold 6,430 shares of Beta Bionics stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total value of $147,890.00. Following the completion of the transaction, the director owned 19,564 shares of the company’s stock, valued at $449,972. The trade was a 24.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mike Mensinger sold 2,650 shares of Beta Bionics stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the completion of the transaction, the insider directly owned 177,390 shares of the company’s stock, valued at $3,902,580. This trade represents a 1.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 107,327 shares of company stock valued at $2,070,421 over the last ninety days. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Beta Bionics

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Beta Bionics in the 2nd quarter worth $52,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Beta Bionics in the fourth quarter worth about $40,437,000. Eversept Partners LP grew its stake in shares of Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares during the period. 12 West Capital Management LP bought a new position in shares of Beta Bionics in the fourth quarter worth approximately $17,520,000. Finally, Bruce & Co. Inc. bought a new stake in shares of Beta Bionics during the 1st quarter valued at $5,518,000.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Wells Fargo upgraded Beta Bionics to “strong-buy” and reportedly initiated coverage with an “overweight” rating and a $28 price target. The endorsement supports the bullish view that the company’s automated insulin-delivery products can gain market share. Wells Fargo upgrade
• Positive Sentiment: Beta Bionics announced an agreement with Senseonics to integrate its iLet Bionic Pancreas and mint systems with the Eversense 365 continuous glucose monitor. A combined system is expected to launch commercially in the fourth quarter of 2026, potentially expanding customer choice and strengthening BBNX’s competitive position in diabetes care. Beta Bionics and Senseonics partnership
• Neutral Sentiment: Analyst support remains generally favorable, with a consensus “Moderate Buy” rating and recent price-target increases. However, the company remains unprofitable, and its negative earnings and net margin limit the immediate fundamental support for the shares.
• Negative Sentiment: Several law firms are publicizing a securities-fraud class action against Beta Bionics. The case covers investors who purchased shares during periods in 2025 and early 2026, with a November 3, 2026 lead-plaintiff deadline. The repeated notices increase visibility around potential legal costs and reputational damage. Beta Bionics securities lawsuit
• Negative Sentiment: The allegations claim Beta Bionics inadequately disclosed FDA concerns, including a June 2025 Form 483 and more than 18,000 iLet-related complaints. The claims are unproven, but they create regulatory and product-safety uncertainty surrounding the company’s core device.
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her direct holdings by about 24.7%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which makes it a weaker discretionary bearish signal, but it may still weigh on sentiment. SEC insider transaction filing

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.